|
|
|
|
|||||
|
|
|
Stryker Corporation (NYSE:SYK) is one of the top low volatility healthcare stocks to buy now. In a report released on July 20, Josh Jennings from TD Cowen maintained a Buy rating on Stryker Corporation (NYSE:SYK) with a price target of $435.00.
The analyst based the optimistic rating on the company’s strong performance in recent quarters and the anticipation of continued momentum.
Jennings stated that Stryker Corporation (NYSE:SYK) has consistently experienced robust growth, reporting a notable 10% organic growth in Q1, which translates to around 11.1% when adjusted for a selling day headwind.
He further stated that Stryker Corporation (NYSE:SYK) is positioned against one of its easier comparisons from 2024 despite an expected slowdown in growth to 8.8% for Q2.
According to Jennings, the company has historically achieved double-digit growth even in the backdrop of challenging benchmarks, suggesting that the present market estimates are well-founded.
Stryker Corporation (NYSE:SYK) is a medical technology company that offers products and services in Neurotechnology, Medical and Surgical, and Orthopedics and Spine. It operates through the MedSurg and Neurotechnology and the Orthopedics and Spine segments.
The company’s medical devices and products include surgical navigation systems, surgical equipment, emergency medical equipment, endoscopic and communications systems, neurosurgical and neurovascular devices, Mako Robotic-Arm Assisted technology, and several other products. Stryker Corporation (NYSE:SYK) holds around 13,000 global patents to shield its products from replication.
While we acknowledge the potential of SYK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| Jul-30 | |
| Jul-29 | |
| Jul-29 | |
| Jul-29 | |
| Jul-29 | |
| Jul-28 | |
| Jul-28 | |
| Jul-28 | |
| Jul-24 | |
| Jul-23 | |
| Jul-23 | |
| Jul-22 | |
| Jul-22 | |
| Jul-22 | |
| Jul-18 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite